Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0079731 (
B-cell lymphoma
)
16,671
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
As a typical product in the Miallard reaction, research on the quantitative detection of furosine is abundant, while its bioactivities and toxic effects are still unclear. Our own work recently demonstrated the induction of furosine on apoptosis in
HepG2
cells, while the related mechanism remained elusive. In this study, the effects of furosine on cell viability and apoptosis were detected to select the proper dosage, and transcriptomics detection and data analysis were performed to screen out the special genes. Additionally, SiRNA fragments of the selected genes were designed and transfected into
HepG2
cells to validate the role of these genes in inducing apoptosis. Results showed that furosine inhibited cell viability and induced cell apoptosis in a dose-dependent manner, as well as activated expressions of the selected genes
STAT1
(signal transducer and activator of transcription 1),
STAT2
(signal transducer and activator of transcription 2)
, UBA7
(ubiquitin-like modifier activating enzyme 7), and
UBE2L6
(ubiquitin-conjugating enzyme E2L6), which significantly affected downstream apoptosis factors
Caspase-3
(cysteinyl aspartate specific proteinase-3)
, Bcl-2
(
B-cell lymphoma
gene-2),
Bax
(BCL2-Associated gene X), and
Caspase-9
(cysteinyl aspartate specific proteinase-9). For the first time, we revealed furosine induced apoptosis through two transcriptional regulators (
STAT1
and
STAT2
) and two ubiquitination-related enzymes (
UBA7
and
UBE2L6
).
...
PMID:Furosine Induced Apoptosis by the Regulation of STAT1/STAT2 and UBA7/UBE2L6 Genes in HepG2 Cells. 2985 9